RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Puma Biotechnology Stock

Puma Biotechnology Employees 2024

Puma Biotechnology Employees

269

Ticker

PBYI

ISIN

US74587V1070

WKN

A1J643

In 2024, Puma Biotechnology employed 269 people, a 0% change from the 269 number of employees in the previous year.

Puma Biotechnology Aktienanalyse

What does Puma Biotechnology do?

Puma Biotechnology Inc. is a biopharmaceutical company based in Los Angeles. It was founded in 2010 and initially focused on the development of innovative cancer treatments. Since then, the company has significantly expanded and now offers a wide range of products and services all centered around cancer treatment. The company's business model revolves around developing drugs that address the need for novel and effective therapies to treat cancer. Puma Biotechnology Inc. is a leading player in this field and has already brought several successful products to market. One of the company's most well-known cancer treatments is Neratinib (also known as Nerlynx), which is used to treat breast cancer. Nerlynx received FDA approval in July 2017. Puma Biotechnology Inc. was founded in 2010 by Alan H. Auerbach, who had previously founded the biopharmaceutical company Cougar Biotechnology and successfully sold it to Johnson & Johnson. The history of Puma Biotechnology Inc. is marked by continuous growth. After its founding, the company acquired exclusive rights to develop neratinib for the treatment of breast cancer. The company has since conducted numerous studies and collected clinical data to prove the efficacy and safety of Nerlynx. After years of research, the medication finally received FDA approval in 2017. Puma Biotechnology Inc. has expanded its offerings since its founding and now offers a wide range of products and services centered around cancer treatment. One of the company's main areas of focus is research and development of cancer treatments. Puma Biotechnology Inc. continuously works on developing new drugs and therapies for a variety of cancer types, including breast cancer, lung cancer, and leukemia. The company is also involved in the production and marketing of pharmaceuticals. Neratinib is the company's most well-known product, but Puma Biotechnology Inc. has also brought other cancer treatments to the market. Additionally, Puma Biotechnology Inc. offers a wide range of services in the field of cancer treatment. The company is involved in the development of diagnostics and preventative measures and also offers training and consultations for doctors and patients. Nerlynx is Puma Biotechnology Inc.'s most well-known product and is now distributed worldwide. The medication is an oral therapeutic used for the adjuvant treatment of early-stage HER2-positive breast cancer in adults following adequate standard adjuvant therapy. It is taken by women who have already undergone chemotherapy, surgery, and radiation therapy. Neratinib works to prevent cancer recurrences by targeting the HER2 receptor, which normally promotes cancer cell growth. The medication blocks these receptors and can therefore inhibit tumor growth. In addition, Puma Biotechnology Inc. has also brought other products to the market, including Ribociclib, which is used in combination with other medications to treat ER-positive, HER2-negative breast cancer. In conclusion, Puma Biotechnology Inc. is a unique and emerging company with a focus on cancer treatments. Since its founding in 2010, the company has become a leading player in cancer combat. Puma Biotechnology Inc. is involved in the development of innovative therapeutic approaches, has achieved numerous medical successes, and brought many promising medications to the market. With Nerlynx, the company has introduced an effective medication for the treatment of breast cancer, and its potential is far from being realized. The company will undoubtedly play an important role in the treatment of cancer in the future. Puma Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Puma Biotechnology's Employee Base

Puma Biotechnology's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Puma Biotechnology's operational capacity and future potential.

Year-to-Year Comparison

Assessing Puma Biotechnology's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Puma Biotechnology's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Puma Biotechnology’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Puma Biotechnology stock

How many employees does Puma Biotechnology have this year?

Puma Biotechnology has 269 undefined employees this year.

How many employees did Puma Biotechnology have compared to the previous year?

Compared to the previous year, Puma Biotechnology had 0% more employees.

What impact did the number of employees have on the company Puma Biotechnology?

The number of employees has a direct impact on the efficiency and productivity of Puma Biotechnology. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Puma Biotechnology?

The number of employees can also have an impact on investors of Puma Biotechnology, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Puma Biotechnology affect the company?

An increase in equity of Puma Biotechnology can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Puma Biotechnology's equity affect the company?

A reduction in equity of Puma Biotechnology can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Puma Biotechnology?

Some factors that can influence the equity of Puma Biotechnology include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Puma Biotechnology so important for investors?

The equity of Puma Biotechnology is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Puma Biotechnology influence the company?

The number of employees at Puma Biotechnology can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Puma Biotechnology evolved in recent years?

In recent years, the number of employees at Puma Biotechnology has changed by 0.

How many employees does Puma Biotechnology currently have?

Puma Biotechnology currently has 269 undefined employees.

Why is the number of employees important for investors of Puma Biotechnology?

The number of employees is important for investors of Puma Biotechnology as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Puma Biotechnology take to change the number of employees?

To change the number of employees, Puma Biotechnology can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Puma Biotechnology pay?

Over the past 12 months, Puma Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Puma Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Puma Biotechnology?

The current dividend yield of Puma Biotechnology is .

When does Puma Biotechnology pay dividends?

Puma Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Puma Biotechnology?

Puma Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Puma Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Puma Biotechnology located?

Puma Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Puma Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Puma Biotechnology from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Puma Biotechnology pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Puma Biotechnology in the year 2023?

In the year 2023, Puma Biotechnology distributed 0 USD as dividends.

In which currency does Puma Biotechnology pay out the dividend?

The dividends of Puma Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Puma Biotechnology

Our stock analysis for Puma Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Puma Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.